Cencora, Inc. $COR Shares Sold by Swedbank AB

Key Points

• Swedbank AB reduced its stake in Cencora by 51.9% in Q4, selling 726,578 shares and leaving it with 672,545 shares (about 0.35% of the company) valued at roughly $227.15 million.
• Cencora missed quarterly estimates with EPS of $4.75 versus $4.80 expected and revenue of $78.36 billion versus $81.09 billion, and provided FY2026 EPS guidance of 17.650–17.900.
• Institutional investors hold 97.52% of the stock, and analysts maintain a consensus "Moderate Buy" with an average price target of $398.17 (market cap ≈ $59.5B, P/E ~36.8).

Swedbank AB lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 51.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 672,545 shares of the company's stock after selling 726,578 shares during the period. Swedbank AB owned approximately 0.35% of Cencora worth $227,152,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. Vestcor Inc boosted its holdings in shares of Cencora by 0.5% in the 3rd quarter. Vestcor Inc now owns 5,196 shares of the company's stock valued at $1,624,000 after acquiring an additional 28 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 30.2% in the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company's stock worth $42,000 after acquiring an additional 29 shares during the period. Cornerstone Wealth Group LLC raised its holdings in shares of Cencora by 1.3% during the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company's stock worth $745,000 after purchasing an additional 30 shares during the last quarter. Apollon Wealth Management LLC lifted its position in Cencora by 0.5% during the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company's stock valued at $2,205,000 after purchasing an additional 30 shares during the period. Finally, Vermillion & White Wealth Management Group LLC lifted its position in Cencora by 31.4% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 138 shares of the company's stock valued at $43,000 after purchasing an additional 33 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Up 0.7%

COR stock opened at $305.89 on Wednesday. Cencora, Inc. has a one year low of $271.00 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm's fifty day moving average is $332.27 and its 200 day moving average is $343.21. The firm has a market cap of $59.50 billion, a PE ratio of 36.77, a P/E/G ratio of 1.42 and a beta of 0.64.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts' consensus estimates of $4.80 by ($0.05). Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts forecast that Cencora, Inc. will post 17.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COR shares. Morgan Stanley set a $380.00 price target on Cencora in a research report on Tuesday, March 17th. Evercore set a $360.00 price objective on Cencora in a report on Wednesday, April 8th. Wells Fargo & Company raised their target price on Cencora from $405.00 to $429.00 and gave the stock an "overweight" rating in a report on Tuesday, February 10th. Weiss Ratings upgraded Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Finally, Robert W. Baird set a $415.00 price target on Cencora in a report on Tuesday, January 13th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $398.17.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.